Sunita MD Sood
Gastroenterology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Looking this up.
Hospitals listed: Kaiser Foundation Hospital and Rehab Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Sunita MD Sood’s office at (408) 972-3000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A105994 · Current
Licensed to practise in California · since 2008 · expires 2026-11-30 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Kaiser Foundation Hospital and Rehab CenterVallejo, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency department · Birthing-friendlyPart of Kaiser Permanente, which runs 41 hospitals in 3 statesPatients rate it 4 of 5 · 74% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.408, Oct 2024 – Sep 2025
See every measure and the patient survey for Kaiser Foundation Hospital and Rehab Center
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.408 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.07) · 176 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.51 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart attack patientsComplications and deaths | 12.6 · 29 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 138 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.5 · 1,910 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 941 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.2 (1.65 to 6.74) · 167 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.53 to 3.92) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.91 (0 to 18.84) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.28) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 842 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.401 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.87 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.401 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.047 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.3 · 203 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.4 · 335 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 64.7 · 31 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.3 · 355 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 133 cases | None | Jul 2023 – Jun 2025 |
What patients said (1,137 patients answered, 21% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 90% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$4,868
Medicare paid this office $4,868 for 22 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
22 Original Medicare patients in 2024. Average age 66 · Health risk score 1.56. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 68%.
The office billed $24,190, Medicare allowed $6,060 and paid $4,868; for 34 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 22 | 34 | 66 | 1.56 | $24,190 | $4,868 |
| 2023 | 13 | 17 | 66 | 0.75 | $24,743 | $2,130 |
| 2019 | 12 | 15 | 64 | 3.33 | $9,445 | $2,088 |
| 2018 | 12 | 16 | 62 | 3.31 | $11,714 | $2,178 |
| 2017 | 12 | 18 | 68 | 1.29 | $15,255 | $1,844 |
| 2016 | 304 | 566 | 70 | 1.66 | $547,397 | $66,697 |
| 2015 | 311 | 679 | 69 | 1.41 | $589,290 | $83,641 |
| 2014 | 285 | 673 | 70 | 1.42 | $567,058 | $77,145 |
| 2013 | 86 | 168 | 69 | 1.36 | $145,373 | $20,948 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2016: 11 services
| Biopsy of large bowel using a flexible endoscope | 75 | $8,872 | $118 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 29 | $6,044 | $208 |
| Short return visit (20+ min) | 79 | $5,612 | $53 |
| New patient visit (45+ min) | 44 | $5,523 | $126 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 52 | $5,168 | $98 |
| Biopsy of large bowel using a flexible endoscope | 12 | $4,270 | $356 |
| New patient visit (30+ min) | 36 | $3,006 | $83 |
| Return visit (30+ min) | 28 | $2,957 | $80 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 31 | $2,613 | $82 |
| Diagnostic exam of large bowel using a flexible endoscope | 16 | $2,408 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,111 | $58 |
2015: 14 services
| Biopsy of large bowel using a flexible endoscope | 72 | $10,507 | $146 |
| New patient visit (45+ min) | 81 | $10,331 | $128 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 33 | $7,449 | $226 |
| Biopsy of large bowel using a flexible endoscope | 18 | $5,669 | $315 |
| Short return visit (20+ min) | 76 | $5,598 | $54 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 60 | $5,453 | $91 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $4,958 | $310 |
| Return visit (30+ min) | 49 | $4,707 | $81 |
| New patient visit (30+ min) | 42 | $3,213 | $77 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $2,206 | $201 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 24 | $1,962 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $1,776 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,766 | $59 |
| Long return visit (40+ min) | 12 | $1,430 | $119 |
2014: 13 services
| Biopsy of large bowel using a flexible endoscope | 84 | $12,623 | $147 |
| New patient visit (45+ min) | 84 | $10,718 | $128 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 39 | $9,930 | $248 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 77 | $6,761 | $86 |
| Short return visit (20+ min) | 72 | $5,651 | $58 |
| Return visit (30+ min) | 45 | $4,743 | $85 |
| New patient visit (60+ min) | 21 | $3,481 | $166 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 14 | $2,906 | $208 |
| New patient visit (30+ min) | 33 | $2,843 | $86 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 28 | $2,440 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,919 | $58 |
| Long return visit (40+ min) | 16 | $1,842 | $115 |
| Injection beneath lining of large bowel using a flexible endoscope | 11 | $260 | $24 |
2013: 5 services
| Biopsy of large bowel using a flexible endoscope | 20 | $3,204 | $160 |
| New patient visit (45+ min) | 21 | $2,789 | $133 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $2,225 | $111 |
| New patient visit (30+ min) | 13 | $1,140 | $88 |
| Short return visit (20+ min) | 13 | $772 | $59 |
Drugs they prescribed that Part D paid
$71,545
Pharmacies billed $71,545 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 503) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
453 generic and 50 brand-name prescriptions · $71,545 in drug cost · 25 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Zenpep | 11 | $17,006 | $1,546 |
| Mesalamine | 17 | $9,223 | $543 |
| Gavilyte-C | 256 | $5,813 | $23 |
| Ursodiol | 18 | $4,270 | $237 |
| Lubiprostone | 22 | $2,067 | $94 |
See all 8 drugs
| Zenpep | 11 | $17,006 | $1,546 |
| Mesalamine | 17 | $9,223 | $543 |
| Gavilyte-C | 256 | $5,813 | $23 |
| Ursodiol | 18 | $4,270 | $237 |
| Lubiprostone | 22 | $2,067 | $94 |
| Budesonide Dr | 13 | $1,073 | $83 |
| Omeprazole | 40 | $417 | $10 |
| Pantoprazole | 30 | $343 | $11 |
Year by year
| 2024 | 503 | 347 | 0% (0) | 10% | $71,545 |
| 2023 | 323 | 170 | 0% (0) | 20% | $67,057 |
| 2022 | 390 | 176 | 0% (0) | 32% | $124,331 |
| 2021 | 290 | 127 | 0% (0) | 15% | $41,802 |
| 2020 | 421 | 165 | 0% (0) | 21% | $56,403 |
| 2019 | 399 | 228 | 0% (0) | 15% | $74,406 |
| 2018 | 383 | 243 | 0% (0) | 33% | $54,605 |
| 2017 | 389 | 252 | 0% (0) | 17% | $42,411 |
| 2016 | 753 | 260 | 0% (0) | 32% | $74,829 |
| 2015 | 740 | 260 | None | 34% | $54,968 |
| 2014 | 538 | 178 | None | 34% | $50,952 |
| 2013 | 63 | 35 | None | 44% | $6,713 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Lialda | 16 | $9,919 | $620 |
| Mesalamine | 11 | $3,754 | $341 |
| Lubiprostone | 12 | $3,452 | $288 |
| Gavilyte-C | 93 | $2,057 | $22 |
| Pantoprazole | 25 | $1,669 | $67 |
| Famotidine | 24 | $618 | $26 |
| Sucralfate | 13 | $560 | $43 |
| Omeprazole | 32 | $295 | $9 |
2022: 11 drugs
| Xifaxan | 13 | $44,096 | $3,392 |
| Lialda | 14 | $9,536 | $681 |
| Lubiprostone | 11 | $6,385 | $580 |
| Gavilyte-C | 73 | $1,209 | $17 |
| Peg-3350 and Electrolytes | 41 | $815 | $20 |
| Sucralfate | 17 | $786 | $46 |
| Lactulose | 21 | $507 | $24 |
| Omeprazole | 50 | $370 | $7 |
| Famotidine | 14 | $153 | $11 |
| Ondansetron | 14 | $148 | $11 |
| Pantoprazole | 11 | $116 | $11 |
2021: 7 drugs
| Gavilyte-C | 54 | $810 | $15 |
| Lactulose | 19 | $636 | $33 |
| Omeprazole | 41 | $422 | $10 |
| Peg-3350 and Electrolytes | 20 | $387 | $19 |
| Spironolactone | 12 | $247 | $21 |
| Famotidine | 16 | $173 | $11 |
| Ondansetron | 11 | $80 | $7 |
2020: 11 drugs
| Linzess | 12 | $8,404 | $700 |
| Lialda | 15 | $3,514 | $234 |
| Mesalamine | 15 | $2,887 | $192 |
| Lactulose | 38 | $1,419 | $37 |
| Gavilyte-C | 70 | $1,410 | $20 |
| Spironolactone | 21 | $635 | $30 |
| Omeprazole | 51 | $604 | $12 |
| Peg-3350 and Electrolytes | 21 | $458 | $22 |
| Famotidine | 35 | $304 | $9 |
| Ondansetron | 24 | $159 | $7 |
| Furosemide | 13 | $157 | $12 |
2019: 5 drugs
| Xifaxan | 16 | $34,444 | $2,153 |
| Gavilyte-C | 146 | $5,229 | $36 |
| Lactulose | 22 | $704 | $32 |
| Omeprazole | 59 | $699 | $12 |
| Famotidine | 11 | $136 | $12 |
2018: 7 drugs
| Gavilyte-C | 90 | $3,266 | $36 |
| Peg 3350-Electrolyte | 87 | $3,181 | $37 |
| Omeprazole | 53 | $627 | $12 |
| Clarithromycin | 12 | $365 | $30 |
| Gavilyte-G | 15 | $329 | $22 |
| Amoxicillin | 12 | $170 | $14 |
| Metronidazole | 16 | $152 | $10 |
2017: 7 drugs
| Lialda | 11 | $12,388 | $1,126 |
| Apriso | 13 | $5,856 | $450 |
| Pentasa | 12 | $4,250 | $354 |
| Gavilyte-C | 174 | $2,958 | $17 |
| Dexilant | 11 | $2,945 | $268 |
| Omeprazole | 56 | $775 | $14 |
| Pantoprazole | 24 | $177 | $7 |
2016: 18 drugs
| Lialda | 21 | $15,928 | $758 |
| Linzess | 11 | $5,547 | $504 |
| Suprep | 49 | $3,935 | $80 |
| Dexilant | 16 | $3,899 | $244 |
| Carafate | 11 | $3,594 | $327 |
| Esomeprazole Magnesium | 16 | $3,360 | $210 |
| Ursodiol | 13 | $2,673 | $206 |
| Balsalazide Disodium | 11 | $2,360 | $215 |
| Omeprazole | 191 | $1,988 | $10 |
| Pantoprazole | 83 | $736 | $9 |
| Peg 3350-Electrolyte | 58 | $557 | $10 |
| Ondansetron Odt | 14 | $530 | $38 |
| Gavilyte-C | 36 | $466 | $13 |
| Polyethylene Glycol 3350 | 13 | $341 | $26 |
| Famotidine | 28 | $238 | $8 |
| Ondansetron | 12 | $212 | $18 |
| Spironolactone | 11 | $113 | $10 |
| Ranitidine | 11 | $33 | $3 |
2015: 18 drugs
| Lialda | 17 | $7,403 | $435 |
| Amitiza | 19 | $5,760 | $303 |
| Ursodiol | 14 | $5,141 | $367 |
| Nexium | 15 | $4,156 | $277 |
| Carafate | 12 | $3,546 | $296 |
| Omeprazole | 195 | $2,396 | $12 |
| Dexilant | 11 | $2,170 | $197 |
| Suprep | 21 | $1,712 | $82 |
| Moviprep | 20 | $1,619 | $81 |
| Peg 3350-Electrolyte | 88 | $878 | $10 |
| Pantoprazole | 54 | $502 | $9 |
| Polyethylene Glycol 3350 | 13 | $482 | $37 |
| Famotidine | 38 | $363 | $10 |
| Gavilyte-C | 30 | $356 | $12 |
| Propranolol | 25 | $328 | $13 |
| Gavilyte-G | 12 | $209 | $17 |
| Lactulose | 16 | $109 | $7 |
| Alendronate | 12 | $57 | $5 |
2014: 13 drugs
| Nexium | 20 | $8,496 | $425 |
| Moviprep | 29 | $2,328 | $80 |
| Carafate | 12 | $1,942 | $162 |
| Omeprazole | 135 | $1,376 | $10 |
| Polyethylene Glycol 3350 | 20 | $979 | $49 |
| Peg 3350-Electrolyte | 49 | $554 | $11 |
| Gavilyte-C | 33 | $407 | $12 |
| Pantoprazole | 31 | $395 | $13 |
| Famotidine | 30 | $241 | $8 |
| Lactulose | 21 | $165 | $8 |
| Peg-3350 and Electrolytes | 11 | $145 | $13 |
| Propranolol | 16 | $112 | $7 |
| Furosemide | 15 | $65 | $4 |
Money from drug and device companies
$23 in 2019
A payment is not proof that care is biased.
| Ucb | Cimzia | $23 | 1 payment
|
See the published payment
| Ucb | Meals · 2019-06-06 | Cimzia | $23 |
Professional record
- NPI
- 1497997324
- Licence
- CA A105994California A105994: Current · expires 2026-11-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 3400 Data Dr, Physician Support Services, Rancho Cordova, CA, 95670
- NPI first listed
- 2009-03-24
- NPI last updated
- 2021-12-17
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.